<DOC>
	<DOCNO>NCT01866930</DOCNO>
	<brief_summary>To evaluate Sustained Virologic Response post treatment Week 12 ( SVR12 ) follow treatment Lambda/RBV/DCV chronic HCV GT-1 , -2 , -3 -4 subject co-infected HIV-1</brief_summary>
	<brief_title>Efficacy Safety Study Pegylated Interferon Lambda-1a With Ribavirin Daclatasvir , Treat naïve Subjects With Chronic HCV Genotypes 1 , 2 , 3 , 4 Who Are Co-infected With HIV</brief_title>
	<detailed_description>Study Classification : Safety/Efficacy Pharmacokinetics/dynamics GT=genotype</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>HCV Genotype1 , 2 , 3 4 treatment naïve ; HCV RNA ≥10,000 IU/mL screening ; HIV1 infection [ ( approximately 200 subject receive HAART , approximately 100 subject receive highly active antiretroviral therapy ( HAART ) ] ; For subject receive HAART , HIV RNA must &lt; 40 copies/mL screen &lt; 200 copies/mL least 8 week prior screen ; CD4 cell count screen must ≥100 cells/μL receive HAART ≥350 cells/μL receive HAART ) Seronegative Hepatitis B Surface Antigen ( HBsAg ) Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive . BMI=weight ( kg ) / [ height ( ) ] 2 screening ; Subjects compensate cirrhosis permit , number subject cap approximately 30 % . If subject cirrhosis , liver biopsy within 3 year prior enrollment required demonstrate absence cirrhosis . If cirrhosis present , prior liver biopsy sufficient . Fibroscan® FibroTest acceptable perform within 1 year prior treatment country liver biopsy require prior treatment noninvasive imaging test approve stag liver disease Subjects mild moderate hemophilia define : 1 . Mildfactor level activity 64 % OR 2 . Moderate define factor level activity 15 % Any evidence liver disease chronic HCV ; Subjects infect human immunodeficiency virus ( HIV2 ) ; Diagnosed suspect hepatocellular carcinoma ; Decompensated liver disease ; Presence acquire immunodeficiency syndrome ( AIDS ) define opportunistic infection within 12 week prior study entry ( AIDSdefining opportunistic infection define CDC , ( CDC , JAMA 1993 Feb 10 ; 269 ( 6 ) :72930 ) Laboratory value : ANC &lt; 1.5 x 109 cells/L ( &lt; 1.2 x 109 cells/L Blacks ) , platelet count &lt; 90 x 109 cells/L , hemoglobin &lt; 11 g/dL female , hemoglobin &lt; 12 g/dL male ; Subjects ( receive HAART ) first initiated antiretroviral therapy within last 8 week prior Day 1 ; however , change require subject 's HAART regimen meet requirement protocol , change allow screen visit . Subjects wait minimum 1 month prior Day 1 repeat HIV viral load confirm , &lt; 40 copies/mL Subjects Zidovudine ( AZT ) , Didanosine ( ddI ) , Stavudine ( d4T ) ; Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement Subjects severe hemophilia ( define &lt; 1 % factor activity level )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>